The Pediatric Gastroesophageal Reflux Disease Symptom and Quality of Life Questionnaire (PGSQ) represents 2 related age-stratified tools developed to assess pediatric gastroesophageal reflux disease (GERD). These include the PGSQ-Cp (for children ages 2 to 8 years, parent/caregiver report) and the PGSQ-A (for adolescents ages 9–17 years). The objective of the present study was to develop and evaluate PGSQ measurement properties.
The PGSQ items were generated based on information from focus groups, expert clinician review, and cognitive debriefing interviews. The symptoms of pediatric GERD and the effect of these symptoms were addressed. The tools were evaluated in a 3-week psychometric evaluation with participants from 11 clinical sites in the United States. The study included other measures such as the Pediatric Quality of Life questionnaire (PedsQL) and clinician-rated GERD severity. After item reduction, internal consistency, reproducibility, construct validity, known-group validity, and responsiveness were assessed.
The 231 participants included 75 parents of children ages 2 to 8 years and 75 children ages 9 to 17 years with GERD and 41 parents of children and 40 children ages 9 to 17 years without GERD. Exploratory factor analysis demonstrated 4 symptom subscales for the PGSQ-Cp and 3 symptom subscales for the PGSQ-A. Both had subscales for total impact and school impact. High to moderate internal consistency was observed, ranging from 0.76 to 0.96 for the PGSQ-Cp and from 0.67 to 0.94 for the PGSQ-A. The PGSQ significantly differentiated between patients with GERD and controls (P < 0.0001, PGSQ-Cp; P < 0.0022–0.0001, PGSQ-A) and demonstrated responsiveness.
These results support the reliability, validity, and responsiveness of both versions of the PGSQ. The instruments should be useful for clinical studies.
*United BioSource Corporation, Bethesda, MD, USA
†Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
‡Takeda Pharmaceuticals North America, Inc, Lake Forest, IL, USA
§University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
||Pediatric Gastroenterology, Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, Canada
¶Pediatric Gastroenterology, Hepatology, and Nutrition, Emory University School of Medicine, Atlanta, GA, USA.
Received 21 April, 2010
Accepted 7 November, 2010
Address correspondence and reprint requests to Leah Kleinman, DrPH, United BioSource Corporation, 7101 Wisconsin Ave, Suite 600, Bethesda, MD 20814 (e-mail: firstname.lastname@example.org).
The work reported here was performed under contract for Takeda by United BioSource Corporation. Authors Leah Kleinman, Laurie Roberts, and Dennis Revicki work for United BioSource Corporation, which performed this work under contract. Authors Susan R. Orenstein, University of Pittsburgh School of Medicine, Pittsburgh, PA; Suzanne Nelson, Feinberg School of Medicine, Northwestern University, Chicago, IL; Ben Gold, Pediatric Gastroenterology, Hepatology, and Nutrition, Emory University School of Medicine, Atlanta, GA; and Eric Hassall, Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, Canada, served as advisory board members and are contracted consultants to Takeda. Reema R. Mody and Omar Dabbous are employees of Takeda. Smita Kothari-Talwar was an employee of TAP Pharmaceuticals at the time this article was written.
The studies described in this article were presented at the American College of Gastroenterology annual meeting, Orlando, FL, October 3–8, 2008; the International Society for Quality of Life Research annual meeting, Toronto, ON, Canada, October 10–13, 2007; and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition annual meeting, Salt Lake City, UT, October 25–27, 2007 and May 3–7, 2008.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal's Web site (www.jpgn.org).